SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 14, 2011--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will present
at the J.P. Morgan 30th Annual Healthcare Conference at 6:30
p.m. EST / 3:30 p.m. PST on Wednesday, January 11, 2012, in San
Francisco. During the presentation, Dr. Morrissey will review the
development plans and priorities for cabozantinib in 2012. He will also
highlight potential future data presentations, discuss the company’s
corporate strategy and financial outlook, and provide a general business
update.
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapeutics for the treatment of cancer. Exelixis is focusing
its proprietary resources and development efforts exclusively on
cabozantinib, its most advanced solely-owned product candidate, in order
to maximize the therapeutic and commercial potential of this compound.
Exelixis believes cabozantinib has the potential to be a high-quality,
differentiated pharmaceutical product that can make a meaningful
difference in the lives of patients. Exelixis has also established a
portfolio of other novel compounds that it believes have the potential
to address serious unmet medical needs. For more information, please
visit the company's web site at www.exelixis.com.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor
Relations and
Corporate Communications
cbutler@exelixis.com
